BioSpace News Archive

Mr. Antoine Turzi, inventor, Regen Lab SA and RegenLab USA LLC are delighted to announce that the United States Patent and Trademark Office (USPTO) has issued two new U.S. patents covering its Thrombin Serum (TS), Platelet Rich Plasma (PRP) and Hyaluronic Acid (HA) technologies

From the discovery of insulin to stem cell research, Canadians have long been at the forefront of groundbreaking innovations in health and biosciences.

St. David’s Women’s Center of Texas recently became one of three facilities in Texas and 37 in the nation to join the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network.

Amgen announced voting results from the Company’s Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately 89 percent of outstanding shares were represented at the meeting.

Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced the Toca 5 Phase 3 clinical trial evaluating Toca 511 & Toca FC in patients with recurrent high grade glioma (HGG) continues without modification following a planned interim analysis of data conducted by an Independent Data Monitoring Committee (IDMC)

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the presentation of data on the economic impact of paroxysmal supraventricular tachycardia

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a late-stage cancer biotechnology company developing intratumoral gene-delivery immunotherapies, today announced that it intends to offer for sale a combination of shares of its common stock and warrants in an underwritten public offering.

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that on May 16, 2019 it received notice (the “Notice”) from the NYSE American LLC that it is not in compliance with Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide

Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will present at the following investor conference in June:

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced results of a new study of U.S. adolescents with peanut allergy that found more than half required a visit to the emergency room or urgent care and one-third required hospitalization as a result of peanut exposure in the past 12 month